Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
- Published In:
- Diabetes & metabolism, 45(5), 409-418 (2019)
- Authors:
- Aroda, V R, Ahmann, A, Cariou, B, Chow, F, Davies, M J, Jódar, E, Mehta, R, Woo, V, Lingvay, I
- Database ID:
- RPEP-04054
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04054APA
Aroda, V R; Ahmann, A; Cariou, B; Chow, F; Davies, M J; Jódar, E; Mehta, R; Woo, V; Lingvay, I. (2019). Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.. Diabetes & metabolism, 45(5), 409-418. https://doi.org/10.1016/j.diabet.2018.12.001
MLA
Aroda, V R, et al. "Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.." Diabetes & metabolism, 2019. https://doi.org/10.1016/j.diabet.2018.12.001
RethinkPeptides
RethinkPeptides Research Database. "Comparative efficacy, safety, and cardiovascular outcomes wi..." RPEP-04054. Retrieved from https://rethinkpeptides.com/research/aroda-2019-comparative-efficacy-safety-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.